Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

10105	Companies
207046	Keywords
137183	Articles
109730	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 02/24/2025 at 11:31, 1 year 1 month ago

Formycon AG: Price Target Adjusted Amid Market Pressures

Buy Recommendation Formycon AG Price Pressure Biosimilar Market Investment Reduction
PRESS RELEASE

published on 02/24/2025 at 11:26, 1 year 1 month ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates its research on Formycon AG, maintaining a Buy recommendation with a decreased target price from EUR 82 to EUR 46 due to higher price pressure and reduced investments in biosimilar portfolio

First Berlin Equity Research Buy Recommendation Research Update Formycon AG Biosimilar Portfolio
BRIEF

published on 02/20/2025 at 06:35, 1 year 1 month ago

Formycon dévoile les données cliniques du biosimilaire d'ustekinumab FYB202 au congrès de l'ECCO

Formycon AG FYB202 Biosimilaire Approbation Réglementaire Données Cliniques
BRIEF

published on 02/20/2025 at 06:35, 1 year 1 month ago

Formycon Unveils Clinical Data for Ustekinumab Biosimilar FYB202 at ECCO Congress

Formycon AG Regulatory Approval Clinical Data Biosimilar FYB202
PRESS RELEASE

published on 02/20/2025 at 06:30, 1 year 1 month ago

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Formycon presents clinical data on ustekinumab biosimilar FYB202 at ECCO Congress, demonstrating comparability with Stelara. FYB202 approved in multiple regions

Clinical Data ECCO Congress Biosimilar Formycon Ustekinumab
BRIEF

published on 02/17/2025 at 09:32, 1 year 1 month ago

Formycon AG fait le point sur ses projets biosimilaires et ses ajustements stratégiques

Stratégie Commerciale Approbation De La FDA Biosimilaires Ajustements Financiers Réductions De Prix
BRIEF

published on 02/17/2025 at 09:32, 1 year 1 month ago

Formycon AG Updates on Biosimilar Projects and Strategic Adjustments

FDA Approval Biosimilars Financial Adjustments Commercial Strategy Price Discounts
PRESS RELEASE

published on 02/17/2025 at 09:27, 1 year 1 month ago

Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon AG provides updates on various biosimilar projects, including terminating phase III trial for FYB206. Conference call on Feb 17, 2025, to discuss recent developments

FDA Conference Call Formycon AG FYB206 Biosimilar Projects
BRIEF

published on 02/17/2025 at 08:10, 1 year 1 month ago

Formycon Updates on Phase III Trial and Valuation Adjustments

Formycon AG FDA Feedback Phase III Trial Commercialization Strategy Biosimilar Valuation
BRIEF

published on 02/17/2025 at 08:10, 1 year 1 month ago

Formycon fait le point sur l'essai de phase III et les ajustements de valorisation

Formycon AG Stratégie De Commercialisation Essai De Phase III Commentaires De La FDA Évaluation Des Biosimilaires

Accesswire

Published on 03/27/2026 at 15:35, 37 minutes ago

SouthGobi Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Published on 03/27/2026 at 12:30, 3 hours 42 minutes ago

Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 4 hours 12 minutes ago

Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 12:00, 4 hours 12 minutes ago

Athena Gold Announces Share Consolidation
Published on 03/27/2026 at 11:00, 5 hours 12 minutes ago

RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation

View all ACCESSWIRE

EQS Group

Published on 03/27/2026 at 15:58, 14 minutes ago

coinIX remains resilient in volatile market environment with balanced annual result | CEO Moritz Schildt sees entry-level prices in the crypto market
Published on 03/27/2026 at 15:50, 22 minutes ago

EQS-Adhoc: Klöckner & Co SE: Worthington Steel announces intention to enter into a domination and profit and loss transfer agreement with Klöckner & Co SE
Published on 03/27/2026 at 15:05, 1 hour 7 minutes ago

Huawei's 6th Global Installer Summit: Gathering the Best Installers to Embrace Renewable Energy Opportunities in the AI Era
Published on 03/27/2026 at 14:31, 1 hour 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 03/27/2026 at 14:31, 1 hour 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited

Les Echos

Published on 03/27/2026 at 07:00, 9 hours 12 minutes ago

WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 21 hours 55 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 21 hours 55 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 22 hours 12 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 22 hours 12 minutes ago

Calendrier financier 2026

View all LES ECHOS COMFI WIRE